MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO), a specialty pharmaceutical company with a proven, proprietary technology, AcuForm, announced today that it will be hosting a conference call on Monday, November 24, 2008 at 4:30 PM EST. The purpose of the call is to discuss the product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 (formerly Gabapentin GR®) for the treatment of pain in the United States, Canada, Mexico and Puerto Rico and to provide an update on Depomed’s business.
